A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa

Phase 1 Terminated 7 enrolled Centocor, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The main purpose of this study is to evaluate the preliminary safety and immunogenicity (ability of an antigen to provoke immune response in the human body) of CNTO 2476, administered subretinally, in participants with advanced retinitis pigmentosa (RP; disease of the eye that leads to loss of vision and blindness) with either light perception only (LP) or hand motion (HM).

Timeline

Start: 2007-04
Primary completion: 2013-08
Completion: 2013-08

Outcome

Outcome not reported

Stopped (Business): “Internal Business Decision”

Publications

Davis JL. The Blunt End: Surgical Challenges of Gene Therapy for Inherited Retinal Diseases. Am J Ophthalmol. 2018 Dec;196:xxv-xxix. doi: 10.1016/j.ajo.2018.08.038. Epub 2018 Sep 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	CNTO 2476	Cell therapy	60000 cells	Other
Subject	CNTO 2476	Cell therapy	120000 cells	Other
Subject	CNTO 2476	Cell therapy	300000 cells	Other
Subject	CNTO 2476	Cell therapy	560000 cells	Other